Suppr超能文献

比较多种 tau-PET 指标作为衰老和阿尔茨海默病的生物标志物。

Comparison of multiple tau-PET measures as biomarkers in aging and Alzheimer's disease.

机构信息

Helen Wills Neuroscience Institute, University of California, Berkeley, Berkeley, CA, United States; German Center for Neurodegenerative Diseases, Magdeburg, Germany.

Helen Wills Neuroscience Institute, University of California, Berkeley, Berkeley, CA, United States.

出版信息

Neuroimage. 2017 Aug 15;157:448-463. doi: 10.1016/j.neuroimage.2017.05.058. Epub 2017 Jun 3.

Abstract

The recent development of tau-specific positron emission tomography (PET) tracers enables in vivo quantification of regional tau pathology, one of the key lesions in Alzheimer's disease (AD). Tau PET imaging may become a useful biomarker for clinical diagnosis and tracking of disease progression but there is no consensus yet on how tau PET signal is best quantified. The goal of the current study was to evaluate multiple whole-brain and region-specific approaches to detect clinically relevant tau PET signal. Two independent cohorts of cognitively normal adults and amyloid-positive (Aβ) patients with mild cognitive impairment (MCI) or AD-dementia underwent [F]AV-1451 PET. Methods for tau tracer quantification included: (i) in vivo Braak staging, (ii) regional uptake in Braak composite regions, (iii) several whole-brain measures of tracer uptake, (iv) regional uptake in AD-vulnerable voxels, and (v) uptake in a priori defined regions. Receiver operating curves characterized accuracy in distinguishing Aβ controls from AD/MCI patients and yielded tau positivity cutoffs. Clinical relevance of tau PET measures was assessed by regressions against cognition and MR imaging measures. Key tracer uptake patterns were identified by a factor analysis and voxel-wise contrasts. Braak staging, global and region-specific tau measures yielded similar diagnostic accuracies, which differed between cohorts. While all tau measures were related to amyloid and global cognition, memory and hippocampal/entorhinal volume/thickness were associated with regional tracer retention in the medial temporal lobe. Key regions of tau accumulation included medial temporal and inferior/middle temporal regions, retrosplenial cortex, and banks of the superior temporal sulcus. Our data indicate that whole-brain tau PET measures might be adequate biomarkers to detect AD-related tau pathology. However, regional measures covering AD-vulnerable regions may increase sensitivity to early tau PET signal, atrophy and memory decline.

摘要

tau 特异性正电子发射断层扫描(PET)示踪剂的最新发展使得能够对 tau 病理学的区域进行体内定量,这是阿尔茨海默病(AD)的关键病变之一。tau PET 成像可能成为临床诊断和疾病进展跟踪的有用生物标志物,但目前尚未就如何最好地定量 tau PET 信号达成共识。本研究的目的是评估多种全脑和区域特异性方法来检测具有临床意义的 tau PET 信号。两组认知正常的成年人和淀粉样蛋白阳性(Aβ)的轻度认知障碍(MCI)或 AD 痴呆患者接受了 [F]AV-1451 PET 检查。tau 示踪剂定量方法包括:(i)体内 Braak 分期,(ii)Braak 综合区域的摄取,(iii)几种全脑示踪剂摄取测量,(iv)AD 易损区的摄取,和(v)预先定义区域的摄取。接收器操作曲线用于区分 Aβ 对照与 AD/MCI 患者的准确性,并得出 tau 阳性的截止值。通过回归分析认知和磁共振成像测量值来评估 tau PET 测量值的临床相关性。通过因子分析和体素对比确定了关键示踪剂摄取模式。Braak 分期、全局和区域特异性 tau 测量值具有相似的诊断准确性,这在两个队列之间有所不同。虽然所有 tau 测量值都与淀粉样蛋白和整体认知相关,但记忆和海马/内嗅皮层体积/厚度与内侧颞叶的区域示踪剂保留相关。tau 积累的关键区域包括内侧颞叶和下/中颞叶、后扣带回皮质和上颞回沟。我们的数据表明,全脑 tau PET 测量值可能是检测 AD 相关 tau 病理学的充分生物标志物。然而,涵盖 AD 易损区域的区域测量值可能会提高对早期 tau PET 信号、萎缩和记忆下降的敏感性。

相似文献

1
Comparison of multiple tau-PET measures as biomarkers in aging and Alzheimer's disease.
Neuroimage. 2017 Aug 15;157:448-463. doi: 10.1016/j.neuroimage.2017.05.058. Epub 2017 Jun 3.
2
3
Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer's disease.
Brain. 2016 May;139(Pt 5):1551-67. doi: 10.1093/brain/aww027. Epub 2016 Mar 8.
5
9
Alzheimer's pathology targets distinct memory networks in the ageing brain.
Brain. 2019 Aug 1;142(8):2492-2509. doi: 10.1093/brain/awz154.

引用本文的文献

2
3
Establishing tau-PET cut-points for cognitive diagnosis with F-PI-2620 in a multi-ethnoracial cohort.
Imaging Neurosci (Camb). 2025 Jun 16;3. doi: 10.1162/IMAG.a.41. eCollection 2025.
4
MRI-free processing of tau PET images for early detection.
Imaging Neurosci (Camb). 2024 Nov 13;2. doi: 10.1162/imag_a_00369. eCollection 2024.
6
Tau, atrophy, and domain-specific cognitive impairment in typical Alzheimer's disease.
Alzheimers Dement. 2025 Jul;21(7):e70511. doi: 10.1002/alz.70511.
7
Developing non-invasive molecular markers for early risk assessment of Alzheimer's disease.
Biomark Neuropsychiatry. 2025 Jun;12. doi: 10.1016/j.bionps.2025.100120. Epub 2025 Jan 28.

本文引用的文献

1
Considerations and code for partial volume correcting [F]-AV-1451 tau PET data.
Data Brief. 2017 Oct 16;15:648-657. doi: 10.1016/j.dib.2017.10.024. eCollection 2017 Dec.
2
Tau PET imaging: present and future directions.
Mol Neurodegener. 2017 Feb 20;12(1):19. doi: 10.1186/s13024-017-0162-3.
3
Tau-PET uptake: Regional variation in average SUVR and impact of amyloid deposition.
Alzheimers Dement (Amst). 2016 Dec 21;6:21-30. doi: 10.1016/j.dadm.2016.12.010. eCollection 2017.
4
Defining imaging biomarker cut points for brain aging and Alzheimer's disease.
Alzheimers Dement. 2017 Mar;13(3):205-216. doi: 10.1016/j.jalz.2016.08.005. Epub 2016 Sep 30.
6
Pharmacokinetic Evaluation of the Tau PET Radiotracer F-T807 (F-AV-1451) in Human Subjects.
J Nucl Med. 2017 Mar;58(3):484-491. doi: 10.2967/jnumed.115.170910. Epub 2016 Sep 22.
7
Reference Tissue-Based Kinetic Evaluation of 18F-AV-1451 for Tau Imaging.
J Nucl Med. 2017 Feb;58(2):332-338. doi: 10.2967/jnumed.116.175273. Epub 2016 Sep 1.
9
In Vivo Tau, Amyloid, and Gray Matter Profiles in the Aging Brain.
J Neurosci. 2016 Jul 13;36(28):7364-74. doi: 10.1523/JNEUROSCI.0639-16.2016.
10
A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers.
Neurology. 2016 Aug 2;87(5):539-47. doi: 10.1212/WNL.0000000000002923. Epub 2016 Jul 1.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验